The Third International Stroke Trial: Thrombolysis (IST-3) in Poland: are we recruiting the right patients?
Polish patients are somewhat different from those recruited in other countries, reflecting clinician's differing areas of uncertainty. These differences will be taken into account in the final trial analysis plan. The trial is still ongoing and more centres are welcome to join.
These cases suggest that a predisposition to develop multiple adenomas, hypothetically caused by a 'benign tumorigenic field effect', although common to all HCAs, may result in different genotypes and phenotypes. Although this is rare, it is expected that more cases with the coexistence of different genotypes will emerge, owing to progress in the use of specific immunohistochemical approaches.